Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.33 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614287 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL5068781 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL16635042 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL3183947 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL16105109 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL22029235 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL25300115 | 0.83 | DPP4 (0.37) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL16838680 | 0.83 | ATM (0.63) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL25261195 | 0.83 | DPP4 (0.37) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL5211015 | 0.83 | ATM (0.63) | ATMDPP4DPP8DPP9PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406609-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3406609-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2018-11-28 | — | — | EP | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2004032834-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20200308170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885DPP4 2492/4885DPP8 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.